Telix Pharmaceuticals (TLX) Current Assets (2023 - 2025)

Telix Pharmaceuticals (TLX) has 3 years of Current Assets data on file, last reported at $330.3 million in Q4 2025.

• Current Assets for Q4 2025 came in at $330.3 million, down 45.02% year-over-year; the trailing twelve-month figure through Dec 2025 was $330.3 million (down 45.02% YoY), and the FY2025 annual result was $330.3 million, down 42.07% from the prior year.
• Current Assets fell to $330.3 million in Q4 2025 per TLX's latest filing, from $600.7 million in the prior quarter.
• Over five years, Current Assets peaked at $600.7 million in Q4 2024 and troughed at $151.4 million in Q4 2023.
• A 3-year average of $360.8 million and a median of $330.3 million in 2025 frame the typical range for Current Assets.
• The sharpest annual moves came in 2024 and 2025: Current Assets soared 296.87% in 2024, then plunged 45.02% in 2025.
• A 3-year view of Current Assets shows it stood at $151.4 million in 2023, then soared by 296.87% to $600.7 million in 2024, then sank by 45.02% to $330.3 million in 2025.
• Business Quant data shows TLX's Current Assets at $330.3 million in Q4 2025, $600.7 million in Q4 2024, and $151.4 million in Q4 2023.